

Papillary thyroid cancer after hematopoietic stem cell transplantation in young age

¹M. Snajderova, ²P. Keslova, ³P. Sykorova, ²P. Sedlacek, ²R. Formankova and ²J. Stary
 ¹Department of Paediatrics, ²Department of Paediatric Haematology and Oncology, ³Department of Nuclear Medicine and Endocrinology, University Hospital Motol, Prague, Czech Republic

Nothing to disclose




Introduction

 Increasing number of survivors following hematopoietic stem cell transplantation (HSCT) leads to necessity to focus also on careful monitoring for late effects. High dose chemotherapy and total body irradiation (TBI) is used for conditioning regimen in many patients.

Transplant characteristics of study group

Preparative regimen

- TBI : 92
- TBI+Busulphan : 10
- Bu/Cy : 114



Benign thyroid nodules (FNAB confirmed)

9 patients (3.1%) 7 after TBI-based regimen 4 treated for AITD all are regularly monitored

• **Thyreopathies** belong to the most frequent among late endocrinopathies.

Objective

Aim of the study was to evaluate **prevalence** of secondary thyroid malignancies after HSCT in young age, especially after TBI.

Subjects

HSCT performed 1989 – 2012

Inclusion criteria

- HSCT in childhood or in adolescence
- Patients surviving more than 1 year after HSCT

• Other : 72

Bu: busulphan Cy: cyclophosphamide

Methods

- All patients were screened yearly for: Serum fT4, TSH, thyroid antibodies, thyroid function
- thyroid ultrasound (US) was performed in 62/288 (21.5%) patients with a Toshiba Nemio 17 ultrasound machine, transducer 7.5 MHz

Results

Malignant tumours

4 patients (1.4%) - 2 male, 2 female all with papillary thyroid carcinoma (PTC) micronodular, T1 or T2 stage all of these patients survive after PTC, disease free Thyroid dysfunction (TDF) after HSCT

Patients with TDF	n (%)	83/288 (29.0%)
Onset of TDF after HCST	years	3.4 (0.5-16.3)
Hypothyroidism subclinical overt primary	n (%)	82 (28.5%) 77 5
Hyperthyroidism	n (%)	2 (0.7%)
AITD (autoimmune thyroiditis)	n (%)	18 (6.2%)


Onset of thyroid dysfunction after HSCT

35 —	
	No of patients
30 +	
25 +	
20 +	
15 🕂	

Characteristics of patients

Patients	n	288
Female/Male	n	110/178
Malignant diagnosis	n	177 (61.5%)
TBI 10-14 Gy	n	91 (32%)
Age at HSCT Median (range)	years	8.2 (0.2 – 20.5)
Age at evaluation Median (range)	years	17.9 (1.8 – 40.5)
Time after HSCT Median (range)	years	8.5 (1.3 – 24.3)

	r∎
PTC diagnosed after HSCT	8.7 years (5.3-15.2)
HSCT for malignant diagnosis	n = 3
TBI-based	all 4 patients
regimen	
Therapy of PTC	thyroidectomy and replacement thyroid hormone in all
	1 with additional ¹³¹ I treatment
Previous therapy	n=3 AITD
for thyreopathy	n=1 hypothyroidism



Conclusions

- Risk of secondary malignancies after HSCT is increasing within the time.
 Long-life late effects monitoring as an important part of post-transplant care is necessary.
- Regular sonographic evaluation of thyroid gland and neck is very important especially more than 5 years after HSCT and namely in all patients after TBI.
 Regular monitoring of thyroid
- function, laboratory parameters and

ultrasound is highly recommended.

• Supported by MH CZ – DRO, University Hospital Motol, Prague, Czech Republic 00064203.